Ihuoma Eneli, MD, MS; Katayoun Sadri, MD; Carlos Camargo, Jr, MD, DrPH, FCCP; and R. Graham Barr, MD, DrPH

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "Ihuoma Eneli, MD, MS; Katayoun Sadri, MD; Carlos Camargo, Jr, MD, DrPH, FCCP; and R. Graham Barr, MD, DrPH"

Ἡρωδίωνν Βιτάλη
5 χρόνια πριν
Προβολές:

1 Ihuoma Eneli, MD, MS; Katayoun Sadri, MD; Carlos Camargo, Jr, MD, DrPH, FCCP; and R. Graham Barr, MD, DrPH ( ) 63% FEV 1 15% (acetaminophen); (asthma); (bronchoconstriction) 30 75% 5 160% [1] From the Sparrow Hospital Pediatric Residency Program (Dr. Sadri) and Department of Pediatrics and Human Development ( ); (Dr. Eneli), Michigan State University, Lansing, MI; Department of Emergency Medicine (Dr. Camargo), Massachusetts [2~9] General Hospital, Harvard Medical School, Boston, MA; and Department of Medicine (Dr. Barr), College of Physicians & TH 2 Surgeons, Mailman School of Public Health, Columbia ( ) [4,6,10] [4,6,7] University, New York, NY. [6,10] Correspondence to: Ihuoma Eneli, MD, MS, Department of Pediatrics and Human Development, Michigan State University, B220 Clinical Center Bldg, East Lansing, MI ; Eneli@msu. edu 1967 Chafee [11] 1 CHEST

2 ECHRIS 1 g 13 ~ 14 Newson [29] [1] 0.52% 0.26% 1995 ICU 8 (33%) Baudouin [30] 24 (89% 13%) ~ 51 OR 1.06 (95%CI 0.77 ~ 1.45); Shaheen [31] 720 OR 1.22 (95%CI 0.87 ~ 1.72); ( 51%) OR 1.79 (95%CI 1.21 ~ 2.65); 980 ( 49%) OR 2.38 (95%CI 1.22 ~ 4.64); P = ~ 32 wk Shaheen [32] 6 mo (OR 6 mo %CI 1.24 ~ 4.40) Barr [33] ( 44 ~ 69 P = RR %CI 1.11 ~ 2.39) mg/kg Lesko [34,35] (RR %CI 0.34 ~ 0.95); (RR %CI 0.25 ~ 1.6) [12] Kogan [12] > 30 d 2 / 3 ( ) (I.U.E. K.S.) [1] 22 [13~28] PUBMED IOWA Cochrane 512

3 1 [29] Newson [29] ( ~ 55 ) [33] (European Community Respiratory Health [ Survey ECHRIS) RR %CI 1.11 ~ 2.39 P = 0.006] ~ 14 1 g ( P = 0.03) ( P = 0.52% ECHRIS 0.12) 1 g 0.26% (P = ) [32] Avon (Avon Longitudinal Study of Parents and Children ALSPAC) (1 574 ) ~ [31] ( ) (> 1 mo) 64% (P = ) 20 ~ ~ 42 mo 2 6 mo (OR 2.34 (OR %CI 1.21 ~ 2.65) 95%CI 1.24 ~ 4.40) (OR %CI ( 2.8 ~ 23) ) 6 mo (OR %CI 1.57 ~ 4.76) 1.5% 0.9% CHEST

4 Lesko [34] [36~51] Schwarz [39] 1 13 (RR mg FEV 1 95%CI 0.34 ~ 0.95) [35] [45] FVC 20% (RR ~ mg %CI 0.25 ~ 1.6) ~ mg 34% FEV 1 15% ( P = ) [41] ( ) 20% ~ 30% [42] [40~42] 2 / mg Szczeklik [37] 300 Szczeklik [38] 150 ~ 600 Spector [47] 650 Ellis [48] 32 Van Diem [51] 200 Leung [45] 500 ~ Schwarz [39] 325 Galindo [50] 500 Kivity [36] Grant [46] Fischer [49] Stricker [44] Ayonrinde [43] 64 ~ Falliers [40] 30 ~ Settipane [42] Settipane [41] ~ FEV 1 20% FVC FEV 1 C3 C IgE FEV 1 20% 2 3 FEV 1 FEF 25~75 20% 2 FEV 1 FEF 25~75 30% FEV 1 16% ~ 33% 34% (P = ) 514

5 [44] [62,63] 68 [43] 15 [30] ; [52] [64] 1 g [65] 2 wk (reactive oxygen species ROS) (O 2- ) (. OH) 1 (ROO - ) [53,54,56] ROS 1 (L-γ- -L- - ) ROS 95% [53] [54~56] [57] ROS [66,67] [54,58~60] [68,69] -S- [55,61] FVC FEV 1 [61] [70] Wu [71] -H 2 O 2 IgE (1) P450 N- N- N- (1) [72,73] ( ) 1 (1) CHEST

6 [53] Dimova [64] IgE [15,50] de Paramo [15] mg P450 IgE mg 2 IgE [74,75] T 1 IgE [16,51] TH 2 IgE ( ) [77] 8 ( ) IgE FEV 1 19% 61% Bagnato [76] 12 FEV 1 ROS C4 D4 [17,24,78] ROS ROS, ( ) [33] Avon [32] ( -2- ) -2 E 2 TH 2 [9,77] TH 1 IgE Davey 516

7 [79] ( ) RR (1.59) (95%CI 1.54 ~ 1.65); Chen [80] 4 Platts-Mills T, et al. Lancet 2001;357: ~ 7 5 Soutar A, et al. Thorax 1997;52: Sporik R, et al. Thorax 2001;56(Suppl):ii58 ii63 7 Sporik R, et al. Thorax 1999;54: [29,31,33] Lesko [81] 10 Devereux G, et al. Clin Exp Allergy 2002;32: Chafee FH, et al. J Allergy 1967;40: Doan T, et al. Ann Allergy 1993;70: Furness J, et al. Thorax 2000;55: Ho SW, et al. BMJ (Clin Res Ed) 1983;287: [81] 20 Karakaya G, et al. Thorax 2001;56: Kumar RK, et al. Hosp Med 1999;60: Martin JA, et al. Clin Exp Allergy 1993;23: Mendizabal SL, et al. Allergy 1998;53: Shin GY, et al. Thorax 2000;55: Vale JA, et al. BMJ (Clin Res Ed) 1983;287:1223 ROS 27 Ownby DR. J Allergy Clin Immunol 1997;99: Ibanez MD, et al. Allergy 1996;51: Newson RB, et al. Eur Respir J 2000;16: Lesko SM, et al. Pediatrics 1999;104:e39 36 Kivity S, et al. Allergy 1999;54: Szczeklik A, et al. BMJ 1975;1: Mannino DM, et al. MMWR CDC Surveill Summ 1998;47: Camargo CA Jr, et al. Arch Intern Med 1999;159: Platts-Mills TA. Curr Allergy Asthma Rep 2002;2: Goldsmith JR, et al. Arch Environ Health 1996;51: Varner AE, et al. Ann Allergy Asthma Immunol 1998;81: Kogan MD, et al. JAMA 1994;272: Karakaya G, et al. Expert Opin Pharmacother 2003;4: Bachmeyer C, et al. South Med J 2002;95: de Paramo BJ, et al. Ann Allergy Asthma Immunol 2000;85: Kalyoncu AF, et al. J Allergy Clin Immunol 1996;98: Vidal C, et al. Ann Allergy Asthma Immunol 1997;79: Baudouin SV, et al. Thorax 1995;50: Shaheen SO, et al. Thorax 2000;55: Shaheen SO, et al. Thorax 2002;57: Barr RG, et al. Am J Respir Crit Care Med 2004;169: USDA Food and Drug Administration. Use caution with pain relievers, January-February Available at: fdac/features/2003/103_pain.html. Accessed January 20, Szczeklik A, et al. J Allergy Clin Immunol 1977;60: Schwarz N, et al. Ann Allergy Asthma Immunol 1996;77: Falliers CJ. J Asthma 1983;20(Suppl 1): Settipane RA, et al. J Allergy Clin Immunol 1995;96: Settipane RA, et al. J Allergy Clin Immunol 1989;84: Ayonrinde OT, et al. Postgrad Med J 2000;76: Stricker BH, et al. BMJ (Clin Res Ed) 1985;291: CHEST

8 45 Leung R, et al. Clin Exp Allergy 1992;22: Grant JA, et al. Ann Allergy Asthma Immunol 2001;87: Spector SL, et al. J Allergy Clin Immunol 1979;64: Ellis M, et al. J Pediatr 1989;114: Fischer TJ, et al. Pediatrics 1983;71: Galindo PA, et al. Allergol Immunopathol (Madr) 1998;26: Van Diem L, et al. Eur J Clin Pharmacol 1990;38: Talbot JC, et al. Br J Clin Pharmacol 1998;45: Kelly FJ. Food Chem Toxicol 1999;37: Rahman I, et al. Eur Respir J 2000;16: Fryer AA, et al. Am J Respir Crit Care Med 2000;161: Smith LJ, et al. Am Rev Respir Dis 1990;141: Corradi M, et al. Am J Respir Crit Care Med 2003;167: Powell CV, et al. Pediatr Pulmonol 1994;18: Plaza V, et al. Thorax 1995;50: Misso NL, et al. Clin Exp Allergy 1996;26: Gilliland FD, et al. Am J Respir Crit Care Med 2002;166: Chen TS, et al. Drug Metab Dispos 1990;18: Micheli L, et al. Environ Health Perspect 1994;102(Suppl 9): Dimova S, et al. Biochem Pharmacol 2000;59: Nuttall SL, et al. J Clin Pharm Ther 2003;28: Jarjour NN, et al. J Lab Clin Med 1994;123: Dohlman AW, et al. Am Rev Respir Dis 1993;148: Stewart RM, et al. Respir Physiol 1981;45: Nishida Y, et al. Inflammation 1985;9: Barnes PJ. Free Radic Biol Med 1990;9: Wu W, et al. J Clin Invest 2000;105: Day RO, et al. Am J Ther 2000;7: Zimmerman HJ, et al. Hepatology 1995;22: Peterson JD, et al. Proc Natl Acad Sci U S A 1998;95: Droge W, et al. Proc Nutr Soc 2000;59: Bagnato GF, et al. Respiration 1999;66: Varner A. Thorax 2000;55: Probst L, et al. J Otolaryngol 1992;21: Davey G, et al. Br J Gen Pract 2002;52: Chen TC, et al. Arch Neurol 1990;47: Lesko SM, et al. Pediatrics 2002;109:E20 CHEST 2005;127: CHEST No.24 In performing a cardiopulmonary exercise test for dyspnea evaluation, which parameter requires an arterial blood gas? A. Dead space to tidal volume ratio. B. Oxygen pulse. C. Ventilatory equivalent for CO 2. D. CO 2 output. E. Peak oxygen uptake. 540 CHEST 518

Σχετικά έγγραφα

Jeffrey J. Swigris, DO; Ware G. Kuschner, MD, FCCP; Jennifer L. Kelsey, PhD; and Michael K. Gould, MD, MS, FCCP

Jeffrey J. Swigris, DO; Ware G. Kuschner, MD, FCCP; Jennifer L. Kelsey, PhD; and Michael K. Gould, MD, MS, FCCP () (1) (2) (3) CT γ-1b (interstitial); (lung diseases); (pulmonary fibrosis) (idiopathic